Mast cells have crucial roles in allergic and other inflammatory diseases. Preclinical
approaches provide circumstantial evidence for mast cell involvement in many diseases, but …

Overview Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast
cells (MCs) in extra‐cutaneous organs. Diagnosis The major criterion is presence of …

Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT
D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) …

Systemic mastocytosis (SM) has greatly benefited from the broad application of precision
medicine techniques to hematolymphoid neoplasms. Sensitive detection of the recurrent KIT …

Midostaurin was a prototype kinase inhibitor, originally developed as a protein kinase C
inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular …

PURPOSE To develop a risk score for patients with advanced systemic mastocytosis
(AdvSM) that integrates clinical and mutation characteristics. PATIENTS AND METHODS …

Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor
overall survival (OS). This study (NCT04695431) compared clinical outcomes between …

Our current recommendations for diagnosing and treating primary mast cell (MC) activation
syndrome make use of the latest studies and consensus guidelines for clinically recognizing …

Mastocytosis is a hematopoietic neoplasm defined by abnormal expansion and focal
accumulation of clonal tissue mast cells in various organ-systems. The disease exhibits a …

Overview Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast
cells (MC) in extra‐cutaneous organs. Diagnosis The major criterion is presence of …